David Bennett has an interesting proposal for future AD/dementia trials. He points out that a large percentage of persons diagnosed with AD actually have mixed pathology, and that solving each of those pathologies with an individual agent is going to be difficult and costly. Instead, he proposes that if one were to target neural reserve — i.e., resilience against dementia — that might be a more tractable strategy.